NCT00210041View on ClinicalTrials.gov

Phase 2 Study of Association Gemcitabine-Cisplatin to Treat Penis Epidermoid Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

February 29, 2004

Primary Completion Date

December 31, 2011

Study Completion Date

December 31, 2012

Conditions
Genital Neoplasms, Male
Interventions
DRUG

Gemcitabine

Gemzar IV infusion 30 minutes Day 1/ Day 15 1250 mg/m²/j

DRUG

Cisplatin

Cisplatin 50 mg/m²/day 1 h IV infusion at Day 1 / Day 15

Trial Locations (11)

Unknown

Centre Paul Papin, Angers

Institut Bergonie, Bordeaux

Centre François Baclesse, Caen

CHU Grenoble, Grenoble

Centre Léon Bérard, Lyon

Institut Paoli Calmette, Marseille

Institut Val d'aurelle, Montpellier

Institut Curie, Paris

Centre Eugène Marquis, Rennes

Centre Médico-Chirurgical Foch, Suresnes

Institut Claudius Regaud, Toulouse

All Listed Sponsors
lead

Institut Claudius Regaud

OTHER

NCT00210041 - Phase 2 Study of Association Gemcitabine-Cisplatin to Treat Penis Epidermoid Carcinoma | Biotech Hunter | Biotech Hunter